



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



p38α MAPK-IN-1

Item No. 40839

CAS Registry No.: 443913-15-3

Formal Name: N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinyl)ethoxy]phenyl]-urea

Synonyms: p38α MAPK Inhibitor 1, p38α Mitogen-activated Protein Kinase-IN-1, p38α Mitogen-activated Protein Kinase Inhibitor 1

MF: C₂₇H₃₅N₅O₃


FW: 477.6

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

p38α MAPK-IN-1 is supplied as a solid. A stock solution may be made by dissolving the p38α MAPK-IN-1 in the solvent of choice, which should be purged with an inert gas. p38α MAPK-IN-1 is soluble (≥10 mg/ml) in ethanol and DMSO and sparingly soluble (1-10 mg/ml) in acetonitrile.

Description

p38α MAPK-IN-1 is an inhibitor of p38α MAPK (IC₅₀ = 5,500 nM in a homogeneous time-resolved fluorescence (HTRF) assay).¹ It inhibits TNF-α production induced by LPS in THP-1 cells (EC₅₀ = 6,200 nM).² p38α MAPK-IN-1 has been used in the study of p38α MAPK inhibitor binding interactions and kinetics.^{1,2}

References

1. Klüter, S., Grütter, C., Naqvi, T., *et al.* Displacement assay for the detection of stabilizers of inactive kinase conformations. *J. Med. Chem.* **53**(1), 357-367 (2010).
2. Regan, J., Breitfelder, S., Cirillo, P., *et al.* Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. *J. Med. Chem.* **45**(14), 2994-3008 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/16/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM